Theravance Biopharma halted its ampreloxetine program after a Phase 3 failure. Discover what the CYPRESS results mean for the company and the neurogenic hypotension market.
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Scinai Immunotherapeutics seeks €12M EU funding to advance PC111 for rare autoimmune skin diseases. Explore the clinical, regulatory, and industry implications.
Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
Senhwa Biosciences and CellType partner to advance silmitasertib with AI. Discover how the collaboration could reshape immunotherapy research.
Hua Medicine’s dorzagliatin wins Hong Kong approval for Type 2 diabetes. Discover what this glucokinase activator milestone means for global diabetes treatment.
Peli BioThermal and Polar Group expand pharmaceutical cold chain solutions in Brazil. Discover what the partnership reveals about biologics logistics.
China approves CEVIRA, the first non-invasive therapy for CIN2 cervical precancer. Discover what this means for treatment pathways and global adoption.